What Aarti Drugs does

Aarti Drugs Limited is a publicly listed Indian manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, specialty chemicals, and finished formulations, established in 1984 as part of the $900 million Aarti Group of Industries. The company operates GMP-certified manufacturing facilities out of Tarapur (Maharashtra) with a corporate office in Mumbai and is the world's largest producer of Fluconazole, Tinidazole, Metformin HCL, Metronidazole, and Ketoconazole APIs. It also holds sole-producer status in India for Ciprofloxacin Hydrochloride, now protected by a five-year anti-dumping duty on Chinese imports effective June 2026. The company carries 12+ global regulatory approvals including USFDA, EDQM, ANVISA, WHO GMP, CFDA, COFEPRIS, TGA, and MFDS Korea, and operates an in-house R&D division with laboratories and kilolabs at Tarapur.

The portfolio spans ~100+ API molecules, intermediates such as fluoroquinolones and nitroimidazoles, specialty chemicals including Salicylic Acid and Benzene Sulphonyl Chloride, a newly launched Amines manufacturing unit, and finished formulations produced through wholly-owned subsidiary Pinnacle Life Science Private Limited. The company's revenue model is B2B contract manufacturing: direct sales to pharmaceutical formulation manufacturers globally through negotiated, quote-based multi-year supply contracts with no publicly disclosed pricing. Customer roster includes major Indian formulators (Sun Pharma, Cipla, Lupin, Mankind, Alkem, Torrent, Zydus Cadila, Intas, Medley) and multinationals (Abbott, Pfizer Zoetis). Recent geographic and product extensions include the March 2026 incorporation of Tripharma Chile SpA for LATAM formulations marketing and a Rs 10 crore capital infusion into Pinnacle Life Science.

FY26 revenue reached Rs 2,565.31 crore (approximately $300M USD) at +7.47% YoY growth, with net profit of Rs 194.92 crore (+15.91% YoY), though Q4 FY26 net profit declined 12.20% YoY on continued investment. The company is led by Chairman, Managing Director, and CEO Prakash Patil and employs 1001-5000 people.

Name

Aarti Drugs

Legal name

Aarti Drugs Limited

Website

https://aartidrugs.co.in

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

1,001–5,000 employees

Short description

Aarti Drugs is a publicly listed Indian API and pharmaceutical intermediates manufacturer, founded in 1984, serving global formulation companies directly with GMP-certified APIs from Tarapur facilities. It is the world's largest producer of five core APIs and the sole Indian producer of Ciprofloxacin Hydrochloride.

Ownership category

akta.pro rank

Product category

Pharmaceutical API Manufacturing

NAICS

Pharmaceutical and Medicine Manufacturing (3254), Other Chemical Product and Preparation Manufacturing (3259)

SIC

Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industry

Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)

Keywords

• Active pharmaceutical ingredients
• Pharma intermediates
• Specialty chemicals
• Bulk drug manufacturing
• API manufacturing

Headquarters

HQ city

Palghar

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Operations, Personnel, Technology or R&D, Infrastructure

Revenue model

1. Active Pharmaceutical Ingredients (APIs): Manufacturing and sale of bulk drug APIs including antibiotics, antidiabetics, and anti-inflammatory products to pharmaceutical formulation manufacturers globally.
2. Pharma Intermediates: Production and supply of pharmaceutical intermediates such as fluoroquinolones and nitroimidazoles supporting complex API development.
3. Specialty Chemicals: Manufacturing specialty chemicals including Salicylic Acid, Amines (Trimethylamine, Dimethylamine, Monomethylamine), Benzene Sulphonyl Chloride, and Methyl Nicotinate for various industrial applications.
4. Formulations: Finished formulations produced through wholly-owned subsidiary Pinnacle Life Science Private Limited.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Aarti Drugs manufactures and sells Active Pharmaceutical Ingredients (APIs), pharma intermediates, specialty chemicals, and amines to pharmaceutical formulation companies globally. It also produces finished formulations through its subsidiary Pinnacle Life Science and offers contract manufacturing services.

Product overview

Aarti Drugs operates as a Contract Development and Manufacturing Organization (CDMO) with a diversified portfolio spanning four main product lines: Active Pharmaceutical Ingredients (APIs) including Ciprofloxacin Hydrochloride, Metformin HCL, Metronidazole, Ketoconazole, Ofloxacin, Fluconazole, and Tinidazole; Pharma Intermediates such as fluoroquinolones and nitroimidazoles; Specialty Chemicals including Salicylic Acid, Trimethylamine, Dimethylamine, Monomethylamine, Benzene Sulphonyl Chloride, and Methyl Nicotinate; and a newly launched Amines Manufacturing Unit. The company also offers Contract Manufacturing services and operates Formulations business through its wholly-owned subsidiary Pinnacle Life Science. With over 100 API molecules and multiple manufacturing facilities, the company serves the global pharmaceutical industry as a preferred supplier of bulk drugs and customized solutions.

Differentiator

Problem solved

Functional benefit

Products and services

• Active Pharmaceutical Ingredients (APIs) High-quality bulk drug APIs including antibiotics (Ciprofloxacin Hydrochloride, Ofloxacin), antidiabetics (Metformin HCL), and anti-inflammatories (Metronidazole, Ketoconazole, Fluconazole, Tinidazole) produced at GMP-certified plants with global regulatory compliance. Sold to pharmaceutical formulation manufacturers globally.
• Pharma Intermediates Broad range of pharmaceutical intermediates including fluoroquinolones and nitroimidazoles that support complex API development with scalable, R&D-backed solutions. Supplied to pharmaceutical manufacturers.
• Specialty Chemicals Chemical products including Salicylic Acid, Trimethylamine, Dimethylamine, Monomethylamine, Benzene Sulphonyl Chloride, and Methyl Nicotinate for pharmaceutical and industrial applications.
• Amines Manufacturing Unit Newly launched amines manufacturing unit producing chemical compounds for pharmaceutical and industrial applications, expanding the company's specialty chemicals portfolio.
• Contract Manufacturing Contract development and manufacturing services for pharmaceutical companies requiring custom manufacturing solutions and flexible production capacity.
• Formulations (Pinnacle Life Science) Finished formulation drug development and manufacturing through wholly-owned subsidiary Pinnacle Life Science, including marketing formulation drugs and participating in government tenders and private pharmaceutical markets.

Quantifiable outcome

• 15% CAGR in sales to Rs 45 billion by FY26
• +2 more outcomes

Named customers17 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

Feature4 records

Partnerships

Three partnerships are on record, tiered core.

• Pinnacle Life Science Private LimitedcoreOthers · 7 March 2026Wholly-owned subsidiary of Aarti Drugs Limited approved for Rs 10 crore investment. Pinnacle Life Science produces formulations and operates as the company's formulation arm. Pinnacle Chile SpA is a subsidiary of Pinnacle Life Science.
• Tripharma Chile SpAcoreOthers · 4 March 2026Wholly-owned step-down subsidiary incorporated in Chile by Pinnacle Chile SpA (subsidiary of Aarti Drugs). The new entity Tripharma Chile SpA will market formulation drugs and participate in government tenders as well as the private pharmaceutical market in Chile, with a share capital subscription of 1,000,000 Chilean pesos.
• Pinnacle Chile SpAcoreOthers · 4 March 2026Subsidiary of Pinnacle Life Science Private Limited through which the company incorporated Tripharma Chile SpA in Chile for formulation drug marketing and government/private pharmaceutical market participation.

Scale indicators14 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Hikal Limited: Indian manufacturer of APIs, intermediates, and specialty chemicals serving pharmaceutical and agrochemical customers; closely comparable on specialty chemicals + API dual model and CDMO-style contract manufacturing.
• Ipca Laboratories: Indian API and formulation manufacturer producing APIs for antimalarials, anti-hypertensives, and pain management; comparable to Aarti Drugs in B2B API sales, domestic manufacturing scale, and exposure to regulated export markets.
• Laurus Labs: Indian API and CDMO manufacturer with vertically integrated formulations, supplying regulated markets with ARV, oncology, and other APIs; highly comparable on scale, customer mix, and export-oriented generic API strategy.
• Suven Pharmaceuticals: Indian CDMO/API manufacturer focused on niche small-molecule APIs with USFDA-approved facilities; comparable to Aarti Drugs in B2B contract manufacturing, regulatory positioning, and API complexity.
• Granules India: Indian manufacturer of APIs, pharmaceutical intermediates, and finished dosages with large-scale, vertically integrated operations; closely comparable on product mix (e.g., paracetamol, metformin, ibuprofen APIs) and customer base among Indian formulators.
• Divi's Laboratories: Indian API manufacturer and CDMO with global regulatory certifications producing generic APIs and custom synthesis for regulated markets; directly comparable to Aarti Drugs in product portfolio, customer base, and export-driven B2B model.
• Solara Active Pharma Sciences: Indian API manufacturer focused on small-molecule APIs serving regulated global markets; comparable to Aarti Drugs on regulatory-driven B2B API model, customer overlap, and product portfolio.
• Dishman Carbogen Amcis: Indian CDMO offering API development, intermediates, and specialty chemicals to global pharma; comparable to Aarti Drugs on contract manufacturing, complex chemistry, and regulatory-quality positioning.

Broad incumbents

• Aurobindo Pharma: Larger Indian pharmaceutical company with vertically integrated API and formulation operations supplying regulated markets; comparable as both an API competitor and a customer-class counterpart with much broader finished product portfolio.
• Cadila Healthcare (Zydus): Larger Indian pharmaceutical company with strong API and formulation footprint; comparable both as an Aarti customer in the dataset and as a broader incumbent with overlapping API interests and regulatory capabilities.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/aarti-drugs-ltd---india

Compliance13 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aarti Drugs